Stay updated on Gantenerumab in Mild Alzheimer Disease Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab in Mild Alzheimer Disease Clinical Trial page.

Latest updates to the Gantenerumab in Mild Alzheimer Disease Clinical Trial page
- Check2 days agoChange DetectedNotice about the government funding lapse banner on the NIH/ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page content appears unchanged between the two screenshots; there are no added or removed sections in the study details, eligibility criteria, or locations.SummaryDifference0.2%

- Check45 days agoChange Detected- Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.SummaryDifference2%

- Check53 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) that were present under v3.0.2. This indicates a content pruning and version update rather than adding new core information.SummaryDifference0.2%

- Check67 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top link was removed. No other substantive content changes were detected.SummaryDifference0.1%

- Check74 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%

Stay in the know with updates to Gantenerumab in Mild Alzheimer Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Mild Alzheimer Disease Clinical Trial page.